

# Gian M Baldin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9395075/publications.pdf>

Version: 2024-02-01

56  
papers

869  
citations

516561

16  
h-index

526166

27  
g-index

57  
all docs

57  
docs citations

57  
times ranked

1193  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2015, 41, 1601-1610.  | 3.9 | 165       |
| 2  | Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.   | 1.2 | 46        |
| 3  | A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48-weeks <sup>TM</sup> observational data. <i>BMC Infectious Diseases</i> , 2017, 17, 658.   | 1.3 | 41        |
| 4  | Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 728-734.  | 1.1 | 40        |
| 5  | Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. <i>Aids</i> , 2017, 31, 457-459.  | 1.0 | 36        |
| 6  | A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected Patients. <i>Antiviral Therapy</i> , 2019, 24, 63-67.   | 0.6 | 33        |
| 7  | Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. <i>HIV Medicine</i> , 2018, 19, 452-454.   | 1.0 | 32        |
| 8  | Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. <i>PLoS ONE</i> , 2017, 12, e0186549.  | 1.1 | 29        |
| 9  | Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1461-1463.  | 1.3 | 27        |
| 10 | Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. <i>Antiviral Research</i> , 2019, 169, 104552.  | 1.9 | 23        |
| 11 | Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. <i>BMC Infectious Diseases</i> , 2019, 19, 59.   | 1.3 | 23        |
| 12 | Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: Table 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2359-2361.   | 1.3 | 22        |
| 13 | Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-1-infected patients in clinical practice: results from a multicentre, observational study. <i>HIV Medicine</i> , 2019, 20, 164-168. | 1.0 | 20        |
| 14 | Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.   | 1.0 | 19        |
| 15 | Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. <i>HIV Medicine</i> , 2021, 22, 843-853.  | 1.0 | 18        |
| 16 | Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 234-237.   | 0.9 | 18        |
| 17 | Salvage Therapy or Simplification of Salvage Regimens with Dolutegravir plus Ritonavir-Boosted Darunavir Dual Therapy in Highly cART-Experienced Subjects: An Italian Cohort. <i>Antiviral Therapy</i> , 2017, 22, 257-262.  | 0.6 | 17        |
| 18 | Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1949-1954.  | 1.3 | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. <i>HIV Clinical Trials</i> , 2018, 19, 242-248.   | 2.0 | 14        |
| 20 | Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016. <i>Epidemiology and Infection</i> , 2019, 147, e89.  | 1.0 | 14        |
| 21 | First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018, 19, 475-484.   | 1.0 | 13        |
| 22 | Cohort profile: The Observational cohort for the study of Dolutegravir in Antiretroviral Combination Regimens (ODOACRE). <i>BMJ Open</i> , 2019, 9, e029960.   | 0.8 | 12        |
| 23 | Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.  | 2.8 | 11        |
| 24 | Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <math>\leq 200</math> cells/mm <sup>3</sup> and HIV-RNA >5 log <sub>10</sub> copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2732-2741. | 1.3 | 11        |
| 25 | Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice. <i>Infezioni in Medicina</i> , 2018, 26, 336-340.  | 0.7 | 11        |
| 26 | Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. <i>HIV Research and Clinical Practice</i> , 2019, 20, 92-98.               | 1.1 | 10        |
| 27 | Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 4-5.   | 0.5 | 10        |
| 28 | Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors. <i>HIV Medicine</i> , 2021, 22, 22-27.   | 1.0 | 10        |
| 29 | An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy. <i>HIV Medicine</i> , 2018, 19, 369-375.   | 1.0 | 9         |
| 30 | No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-dolutegravir. <i>Aids</i> , 2020, 34, 956-957.   | 1.0 | 9         |
| 31 | Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 4-10.  | 0.5 | 9         |
| 32 | Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak. <i>Diagnostics</i> , 2021, 11, 1154.   | 1.3 | 9         |
| 33 | Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 429-432.                                  | 0.5 | 9         |
| 34 | Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.   | 1.3 | 8         |
| 35 | Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.   | 1.1 | 7         |
| 36 | Predictors of choice of initial antifungal treatment in intraabdominal candidiasis. <i>Clinical Microbiology and Infection</i> , 2016, 22, 719-724.  | 2.8 | 7         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Has COVID-19 changed the approach to HIV diagnosis?. <i>Medicine (United States)</i> , 2021, 100, e27418.   | 0.4 | 7         |
| 38 | Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 487-490. | 1.1 | 6         |
| 39 | Shall We Dance? Extending TANGO™s Results to Clinical Practice. <i>Clinical Infectious Diseases</i> , 2020, 71, e200-e201.  | 2.9 | 6         |
| 40 | Dolutegravir plus lamivudine for the treatment of HIV-1 infection. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 279-292.  | 2.0 | 6         |
| 41 | Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 486-488.   | 0.5 | 6         |
| 42 | Lamivudine-based maintenance antiretroviral therapies in patients living with <sc>HIV</sc> with suppressed HIV <sc>RNA</sc>: derivation of a predictive score for virological failure. <i>HIV Medicine</i> , 2019, 20, 624-627.   | 1.0 | 5         |
| 43 | Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. <i>Viruses</i> , 2022, 14, 163.   | 1.5 | 5         |
| 44 | Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1317-1332.   | 1.0 | 4         |
| 45 | HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART. <i>Journal of Clinical Virology</i> , 2018, 103, 57-62.   | 1.6 | 3         |
| 46 | HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 256-257.   | 0.5 | 3         |
| 47 | Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study. <i>Infezioni in Medicina</i> , 2019, 27, 410-414.  | 0.7 | 3         |
| 48 | Real-life findings on the impact of the COVID-19 pandemic on HIV care. <i>Antiviral Therapy</i> , 2021, 26, 84-86.  | 0.6 | 2         |
| 49 | Case Report: Multifocal Tubercular Osteomyelitis of the Spine and Bilateral Dactylitis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 494-497.  | 0.6 | 2         |
| 50 | Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2470-2472.  | 1.3 | 0         |
| 51 | “How much raltegravir do you take?”™ The answer may not be so obvious: an accidental finding from clinical practice. <i>HIV Medicine</i> , 2020, 21, e1-e2.   | 1.0 | 0         |
| 52 | Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 350-356.  | 0.5 | 0         |
| 53 | Re: “No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir” by Calza <i>et al.</i> . <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 333-334.   | 0.5 | 0         |
| 54 | Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience. <i>Medicine (United States)</i> , 2021, 100, e27418.  | 0.4 | 0         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | C87â€fTHE SHORTâ€“TERM PROGNOSTIC SIGNIFICANCE OF BASELINE TROPONIN LEVELS IN PATIENTS HOSPITALIZED FOR COVIDâ€“19. European Heart Journal Supplements, 2022, 24, .                           | 0.0 | 0         |
| 56 | P404â€fCAN THE BASELINE NTâ€“PROBNP LEVEL BE USED AS A PROGNOSTIC MARKER IN PATIENTS HOSPITALIZED FOR COVIDâ€“19? A SINGLE CENTRE EXPERIENCE. European Heart Journal Supplements, 2022, 24, . | 0.0 | 0         |